Tag: EXCESSIVE DAYTIME SLEEPINESS

Narcolepsy Product & Vendor Updates Sleep Pharmaceuticals

Harmony Strengthens Patent With ANDA Settlement

Harmony Biosciences Holdings, Inc., today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will […]

Narcolepsy Industry News & Updates Sleep Pharmaceuticals

Avadel Pharmaceuticals Presents New Data on LUMRYZ ER at SLEEP 2025

 Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 […]

Jazz Pharmaceuticals AAN, Phase 4 DUET trial, Xywav, Epidiolex
Sleep Pharmaceuticals

Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav at AAN

Jazz Pharmaceuticals plc announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April 5-9, 2025, in San Diego. Data presented at the meeting includes an updated presentation of top-line results of the open-label, single-arm, Phase 4 DUET (Develop hypersomnia Understanding by Evaluating […]

WAKIX Revenue to Exceed $1B in 2026
Sleep Pharmaceuticals

Promising Results for Pitolisant in Prader-Willi Syndrome

Harmony Biosciences Holdings, Inc. announced the presentation of new secondary endpoint data, including improvements in behavioral disturbances, from its Phase 2 signal-detection study evaluating pitolisant for the treatment of excessive daytime sleepiness (EDS) in Prader-Willi syndrome (PWS) at the 2023 Foundation for Prader-Willi Research (FPWR) Symposium and Family Conference. The […]

excessive sleepiness
Patient Health & Care

New Clinical Guideline Recommendations for Sleep Disorders that Cause Excessive Sleepiness

A new clinical practice guideline developed by the American Academy of Sleep Medicine provides recommendations for the treatment of central disorders of hypersomnolence. These sleep disorders cause excessive sleepiness despite a sufficient amount of nocturnal sleep. The guideline, available online as an accepted paper in the Journal of Clinical Sleep Medicine, […]

xywave jazz narcolepsy cataplexy eds
Sleep Pharmaceuticals Idiopathic Hypersomnia

Jazz Presents Phase 3 Results of Xywav in Adults with Idiopathic Hypersomnia

Jazz Pharmaceuticals plc has announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be presented during the Clinical Trials Plenary Session of the 2021 American Academy of Neurology (AAN) Annual Meeting. The presentation will further […]